Company intelligence / Profile preview

Ina Pharms

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Ina Pharms is a preclinical-stage biotechnology company focused on developing novel therapeutics for the treatment of chronic and neuropathic pain. The company's lead research centers on G protein-coupled receptor 151 (GPR151), a target highly expressed in the dorsal root ganglion and associated with pain signaling pathways. By developing selective small molecule modulators of GPR151, Ina Pharms aims to provide effective pain relief with a reduced risk of side effects compared to traditional opioids. The company is currently advancing its lead candidates through optimization and early safety studies.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Ina Pharms.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ina Pharms.

Explore the full profile